The phase II KAMELEON trial looked at the relationship between HER2 expression and trastuzumab emtansine (T-DM1) in patients with biomarker-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. This evidence concerns the gene ERBB2 and pancreatic neoplasm.